We are monitoring the impact of COVID-19 on MEA Antacid Market Get in touch with us for detailed analysis Know More
Share on

Middle East & Africa Antacid Market Research Report - Segmented By Drug Class, Formulation Type, Distribution Channel & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 2270
Pages: 145

Middle East & Africa Antacid Market Size & Growth (2022 to 2027):

The Size of the MEA Antacid Market was valued at USD 1.34 billion in 2022 and is poised to reach USD 1.58 billion by the end of 2027, growing at a CAGR of 3.31% during the forecast period 2022 to 2027.

Antacids are usually over-the-counter (OTC) medications to relieve heartburn, indigestion, and other gastrointestinal diseases. Manufacturers in the MEA antacids market are focusing on formulating different drug solutions techniques to support a variety of products.

In 2050, this population is estimated to increase to 1.55 billion. Furthermore, the global population was aged 65 years or over has seen an increase from 6.23% in the early 1990s to 9.56% in 2019, with over 65% of the senior population suffering from acid reflux. In addition, geriatric patients are significant consumers of antacids as they are often suffering from indigestion, GERD, IBS, peptic ulcers, and others. These critical factors will boost the antacid market in the MEA region.

Patients suffer from several symptomatic disorders, such as erosive esophagitis, duodenal ulcers, Barrett esophagus, and esophageal cancer. Therefore, a combination of therapies is used for the treatment, requiring antacids to neutralize the harmful effects of gastric HCL. In addition, other factors such as poor lifestyle choices, inadequate sleep, stress, obesity, irregular dietary habits, and drug abuse have increased acidity level of the stomach and led to gastroesophageal reflux disease, whereby driving the MEA antacids market growth.

There has been a high incidence of Gastroesophageal Reflux Disease (GERD) globally over the several years. As per the recent article published by the International Foundation for Gastrointestinal Disorders in 2017, the prevalence of GERD was around 18.1% to 28.5% in North America, 9.5% to 26.6% in Europe, 3% to 8.5% in East Asia, 9.56% to 33.9% in the Middle East, 12.56% in Australia, and 23.5% in South America. Therefore, the launch of melt-in-mouth antacids has increased the market growth rate.

The side effects associated with antacids are major limiting factors in the market. Antacids common side effects include dose-dependent rebound hyperacidity, alkali syndrome, constipation, osteomalacia, hypophosphatemia, and reduced drug efficacy due to synergistic effects when combined with other acidic drugs. Moreover, other alternatives in the market will restrain the market.

This research report on the MEA Antacid Market has been segmented and sub-segmented into the following categories.

By Drug Class: 

  • Proton Pump Inhibitors
  • H2 Antagonist
  • Acid Neutralizers
  • Pro-motility Agents

By Formulation Type: 

  • Tablet
  • Liquid
  • Powder

By Distribution Channel: 

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the Saudi Arabia antacid market and the UAE antacid market are estimated to grow significantly due to the growing geriatric population and well-developed healthcare facilities. Also, the increasing trend toward self-medication and purchase of products via E-commerce websites is on the rise.

In Saudi Arabia, a recent study conducted in the western region and Riyadh, performed using the GerdQ questionnaire of score ≥ 8 as a diagnostic criterion for GERD, recorded the prevalence range at 23.48% at 45.44%. The increase in these numbers and awareness about antacids will drive the market in the years to come.

Meanwhile, according to the aster clinic, factors such as lack of physical activity coupled with dense, fast food and spicy food consumption have resulted in the UAE region. It is having one of the highest rates of obesity in the world. GERD prevalence is recorded at nearly 3.12 million individuals across the seven Emirates nations.

KEY MARKET PLAYERS

Noteworthy companies l in the MEA Antacid Market profiled in this report are Sun Pharma, Digene (Abbott India), Pudin Hara (Dabur), Gelusil (Pfizer), GlaxoSmithKline plc, Abbott Laboratories, Pfizer, Inc., 

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods 

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Class                   

                                5.1.1 Introduction           

                                5.1.2 Proton Pump Inhibitors     

                                5.1.3 H2 Antagonist        

                                5.1.4 Pro-motility agents              

                                5.1.5 Acid Neutralizers  

                                5.1.6 Y-o-Y Growth Analysis, By Drug Class          

                                5.1.7 Market Attractiveness Analysis, Drug Class              

                                5.1.8 Market Share Analysis, By Drug Class         

                5.2 Formulation Type                    

                                5.2.1 Introduction           

                                5.2.2 Tablet        

                                5.2.3 Liquid        

                                5.2.4 Powder    

                                5.2.5 Y-o-Y Growth Analysis, By Formulation Type            

                                5.2.6 Market Attractiveness Analysis, By Formulation Type          

                                5.2.7 Market Share Analysis, By Formulation Type           

                5.3 Distribution Channel                               

                                5.3.1 Introduction           

                                5.3.2 Hospital Pharmacies            

                                5.3.3 Retail pharmacies 

                                5.3.4 Other        

                                5.3.5 Y-o-Y Growth Analysis, By Distribution Channel      

                                5.3.6  Market Attractiveness Analysis, By Distribution Channel   

                                5.3.7 Market Share Analysis, By Distribution Channel      

                5.4 Disease Indications 

                                5.4.1 Introduction           

                                5.4.2 Cancer      

                                5.4.3 CardiovascularDisorders    

                                5.4.4 Neurological Disorders       

                                5.4.5 Immunological Disorders  

                                5.4.6 Other Diseases      

                                5.4.7 Y-o-Y Growth Analysis, By Disease Indications         

                                5.4.8  Market Attractiveness Analysis, By Disease Indications      

                                5.4.9  Market Share Analysis, By Disease Indications       

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Class

                                                6.1.3.3 By Formulation Type

                                                6.1.3.4 By Distribution Channel

                                6.1.4 Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Class

                                                6.1.4.3 By Formulation Type

                                                6.1.4.4 By Distribution Channel

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Class

                                                6.1.5.3 By Formulation Type

                                                6.1.5.4 By Distribution Channel

                6.2 Latin America                             

                                6.2.1 Introduction           

                                6.2.2 Middle East

                                6.2.3 Africa           

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Glaxo Smith                

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Abbott Laboratories               

                8.3 Pfizer Inc                     

                8.4 Sun Pharmaceuticals                              

                8.5 Consumer Health                     

                8.6 Dabur                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                

  1. Middle East & Africa Antacid Market, By Region, From 2022 - 2027 (USD Billion)
  2. Middle East & Africa Antacid Market, By Drug Class, From 2022 - 2027 (USD Billion)
  3. Middle East & Africa Proton Pump Inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  4. Middle East & Africa H2 Antagonist Market, By Region, From 2022 - 2027 (USD Billion)
  5. Middle East & Africa Acid Neutralizers Market, By Region, From 2022 - 2027 (USD Billion)
  6. Middle East & Africa Pro-Motility Agents Market, By Region, From 2022 - 2027 (USD Billion)
  7. Middle East & Africa Antacid Market, By Formulation type, From 2022 - 2027 (USD Billion)
  8. Middle East & Africa Tablet Market, By Region, From 2022 - 2027 (USD Billion)
  9. Middle East & Africa Liquid Market, By Region, From 2022 - 2027 (USD Billion)
  10. Middle East & Africa Powder Market, By Region, From 2022 - 2027 (USD Billion)
  11. Middle East & Africa Antacid Market, By Distribution Channel, From 2022 - 2027 (USD Billion)
  12. Middle East & Africa Hospital Pharmacies Market, By Region, From 2022 - 2027 (USD Billion)
  13. Middle East & Africa Retail Pharmacies Market, By Region, From 2022 - 2027 (USD Billion)
  14. Middle East & Africa Others Market, By Region, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample